SIGHT
FOR
LIFE
Transforming lives by developing innovative treatments for ocular diseases that helps restore sight for life
2.2 B
people with vision impairement
2.64 B
people who have myopia
460 M
people with high myopia
IMPACT WITH NUMBERS
Theialife's commitment to innovation is reflected in our impressive metrics, demonstrating our impact in ophthalmology
Our lead asset, 7MX is poised to become the first oral therapy for early-onset-pediatric-myopia and is set to enter global Phase III clinical trials in 2025.
JOIN US
Building the future
of ophthalmology
We are on a mission to tackle some of the world's biggest health challenges, trying to find solutions where none exist. At Theialife, we seek partners who want to push back the boundaries of innovation on behalf of patients.
This molecular platform has a innovative approach to potentially address neovascular age related macular degeneration & Pterygium.
XP
Our lead molecular platform that has the capability to address various indications including Pediatric Myopia, Dry-Eye Disease & UV-B Cataract.
ND10
Using an innovative approach to drug discovery, this molecular platform is uniquely positioned to address Keratoconus & Corneal blindness.
rHCT3
2o years of real-world clinical usage in Denmark, with nil reported adverse effects.
PROPRIETARY OPTHAMOLOGY PLATFORM
An innovative platform that addresses various ophthalmology unmet needs using novel molecules.
World's First Clinical Phase-3 Ready Oral Therapeutic For Paediatric Myopia
ESG
Daily disposable contact lenses generate approx. 1 KG of plastic waste per year per user
150 Billion contact lenses produced annually
4 Million (approx.) children using contact lenses to treat myopia
VS.
SUSTAINABLE VISIONARY SCIENCE
1 oral tablet of Theialife's drug produced through fermentation using renewable water sources.
0.1 kg CO2 per tablet.
MEET US AT .